We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Backs AZ Gout Drug Despite Safety Concerns
FDA Advisory Panel Backs AZ Gout Drug Despite Safety Concerns
In a conflicted decision with most members suggesting postmarketing studies, an FDA advisory panel voted 10 to four Friday to recommend approval of AstraZeneca’s gout drug lesinurad.